Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health, Inc. officer Irene Becklund reported equity transactions dated 12/15/2025. She acquired 17,986 shares of Class A Common Stock through the vesting and settlement of restricted stock units, and 8,867 shares of Class A Common Stock were withheld by the issuer at $36.25 per share to cover tax withholding obligations. After these transactions she directly owned 10,537 shares of Class A Common Stock.
The report also lists multiple restricted stock unit (RSU) awards, each representing a contingent right to receive one share of Class A Common Stock for each RSU. These RSUs are subject to service-based vesting over four-year periods, generally in substantially equal quarterly installments on March 15, June 15, September 15 and December 15, with initial vesting dates beginning on various company quarterly vesting dates from 06/15/2022 through 06/15/2025.
Hims & Hers Health reported insider equity activity by its Chief Financial Officer, Oluyemi Okupe. On December 15, 2025, restricted stock units (RSUs) vested and were settled into 105,201 shares of Class A common stock. The issuer withheld 58,010 shares at $36.25 per share to cover tax withholding obligations from this vesting, leaving Okupe with 117,423 shares held directly and 7,853 shares held indirectly through a separate property trust.
The RSUs each represent a contingent right to receive one share of Class A common stock. Several RSU grants are subject to four-year service-based vesting schedules on quarterly dates of March 15, June 15, September 15 and December 15, with different grants beginning to vest on March 15, 2023, June 15, 2023, June 15, 2024 and June 15, 2025.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported equity compensation activity involving the company’s Class A common stock on December 15, 2025. He acquired 72,106 shares through the vesting and settlement of previously granted restricted stock units, increasing his direct holdings before tax withholding.
To cover related tax obligations, 39,870 shares were withheld by the company at a price of $36.25 per share. After these transactions, Chi directly beneficially owned 318,911 shares of Class A common stock. Multiple restricted stock unit awards continue to vest on a quarterly schedule over four-year service-based periods, with different grants beginning vesting on various Company Quarterly Vesting Dates from June 15, 2022 through June 15, 2025.
Hims & Hers Health, Inc. reported an insider equity transaction by director and Chief Policy Officer Deborah M Autor. On December 15, 2025, 7,054 restricted stock units (RSUs) were converted into the same number of Class A common shares, increasing her directly held stake to 13,229 shares.
The RSUs carry a service-based vesting schedule over three years. One third vests on December 15, 2025, another third on December 15, 2026, and the final third on December 15, 2027. After this transaction, Autor continues to hold 14,110 RSUs, each representing the right to receive one Class A common share at no cash exercise price.
Hims & Hers Health, Inc. director Andrea G. Perez Garcia reported a stock sale in a Form 4 filing. On 12/09/2025, the reporting person sold 2,500 shares of Class A common stock of Hims & Hers Health, Inc. at a price of $39.17 per share, in a transaction coded "S" for sale.
After this transaction, the reporting person beneficially owns 80,166 shares of Hims & Hers Health, Inc. Class A common stock in direct ownership. The filing notes that it was submitted as a Form 4 for one reporting person who serves as a director of the company.
An affiliate of HIMS has filed a notice of proposed sale of restricted securities under Rule 144. The filing covers the planned sale of 2,500 Class A shares through Fidelity Brokerage Services LLC on or about 12/09/2025, on the NYSE, with an indicated aggregate market value of $97,925.00. The Class A shares were originally acquired from the issuer on 03/15/2022 via restricted stock vesting as compensation. The table notes that 219,270,891 Class A shares were outstanding at the time referenced, and the seller represents that they are not aware of undisclosed material adverse information about the issuer.
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum, a director and more than 10% owner, reported changes in his Class A common stock holdings dated 11/28/2025. The filing shows internal transfers among his direct ownership and various family trusts, including a transfer of 712,500 shares from the Andrew Dudum 2015 Trust to his direct holdings and an annuity payment-in-kind of 115,996 shares from the AD 2022 GRAT 3 to that trust.
The report also discloses a gift of 1,078,549 shares from the AD 2022 GRAT 3 to the Dudum Legacy 2021 Trust, recorded at a price of $0 with transaction code "G" (gift). After these movements, Dudum continues to hold a significant stake in Hims & Hers through a combination of direct ownership and multiple family and GRAT trusts.
Hims & Hers Health, Inc. Chief Operating Officer Michael Chi reported an insider transaction involving the company’s Class A common stock. On 12/01/2025, he transferred 5,000 shares as a gift to a donor-advised fund, with no sale proceeds reported (price shown as $0).
After this charitable transfer, Chi beneficially owns 286,675 Class A shares. This total includes 236 shares acquired on November 20, 2025 under the Hims & Hers Health, Inc. 2020 Employee Stock Purchase Plan. The filing is made as a Form 4 for a single reporting person.
Hims & Hers Health (HIMS) insider trade reported: the company’s Chief Legal Officer, listed as an officer of the issuer, sold 2,631 shares of Class A common stock on 11/24/2025. The sale was reported at a price of $35.22 per share and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 28, 2024, which is designed to allow executives to sell shares according to a preset schedule. After this transaction, the reporting person directly beneficially owns 153,225 shares of Class A common stock.
Hims & Hers Health, Inc. (HIMS) CFO Oluyemi Okupe reported option exercises and a share sale. On 11/17/2025, the executive exercised stock options for 7,615 Class A common shares at $11.53 and 15,572 shares at $5.01, increasing direct holdings before any sale.
On the same date, 23,187 Class A common shares were sold at an average weighted price of $36.809 under a Rule 10b5-1 trading plan adopted on May 21, 2025. Following these transactions, the executive directly owns 70,232 Class A common shares and indirectly owns 7,853 shares through the Oluyemi Okupe Separate Property Trust dated 9‑1‑2021.
The report also shows remaining stock options: 7,615 options with an exercise price of $11.53 and 48,554 options outstanding after the exercise, and 15,572 options at $5.01 with 158,808 options remaining. These options vest over multi-year schedules based on continued service.